Death Panels for Babies in Obamacare? Kids With RSV Should Beware
The point of the article is that no viable treatment exists for RSV, and the one that does exist is so expensive that Medicaid often refuses to cover it. If only a vaccine was available... Oh that's right, Novavax has one, and based on the Phase 2 results - it works! NVAX RSV-F is one of those "unmet medical needs" we so often hear talked about, with unlimited market potential.
Full article can be seen by googling "Death Panels for Babies in Obamacare? Kids With RSV Should Beware"
Every year between November and March, there are outbreaks of Respiratory Syncytial Virus, an illness similar to the flu.
RSV is the leading cause of pneumonia and bronchiolitis, and hospitalization for children under the age of one; premature infants and children before the age of two with congenital heart or chronic lung disease are considered to be at highest risk.
Each year RSV causes two million hospitalizations and 14,000 deaths. In addition, RSV disproportionately affects minority and especially African American babies, who, according to the Centers for Disease Control, are 59% percent more likely to be born prematurely than white infants.
While there is no vaccine for RSV, there is an FDA-approved treatment available. When it became available in 1997, the American Academy of Pediatrics issued evidence-based guidelines for its use, recommending that the treatment be administered once per month during outbreak season (an average of five months total).
But in 2009, with no clear medical evidence for doing so, the AAP both shrunk the pool of eligible infants and reduced the number of RSV treatments that would be made available – for some babies down to 3 doses, while for others as low as 1 dose. The only clear reason given was cost.
Unfortunately, the AAP’s guidelines are widely implemented by Medicaid and insurance providers, who in turn followed suit and greatly reduced coverage.